Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Moodys
Johnson and Johnson
AstraZeneca
Colorcon

Last Updated: May 20, 2022

FENOGLIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Fenoglide, and what generic alternatives are available?

Fenoglide is a drug marketed by Salix and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-nine patent family members in eleven countries.

The generic ingredient in FENOGLIDE is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Fenoglide

A generic version of FENOGLIDE was approved as fenofibrate by RHODES PHARMS on May 13th, 2005.

  Sign up for a Free Trial

Drug patent expirations by year for FENOGLIDE
Drug Prices for FENOGLIDE

See drug prices for FENOGLIDE

Drug Sales Revenue Trends for FENOGLIDE

See drug sales revenues for FENOGLIDE

Recent Clinical Trials for FENOGLIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Phase 2
The Scripps Research InstitutePhase 2

See all FENOGLIDE clinical trials

Pharmacology for FENOGLIDE
Anatomical Therapeutic Chemical (ATC) Classes for FENOGLIDE
Paragraph IV (Patent) Challenges for FENOGLIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FENOGLIDE Tablets fenofibrate 40 mg and 120 mg 022118 1 2010-03-17

US Patents and Regulatory Information for FENOGLIDE

FENOGLIDE is protected by four US patents.

Patents protecting FENOGLIDE

Solid dosage form comprising a fibrate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Solid dosage form comprising a fibrate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA

Solid dosage form comprising a fibrate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES

Tablet comprising a fibrate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Salix FENOGLIDE fenofibrate TABLET;ORAL 022118-002 Aug 10, 2007 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Salix FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Salix FENOGLIDE fenofibrate TABLET;ORAL 022118-002 Aug 10, 2007 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Salix FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Salix FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for FENOGLIDE

See the table below for patents covering FENOGLIDE around the world.

Country Patent Number Title Estimated Expiration
Canada 2582403 COMPOSITIONS PHARMACEUTIQUES COMPRENANT DU FENOFIBRATE ET DEL'ATORVASTATINE (PHARMACEUTICAL COMPOSITIONS COMPRISING FENOFIBRATE AND ATORVASTATIN) See Plans and Pricing
World Intellectual Property Organization (WIPO) 2006037347 See Plans and Pricing
Japan 2007508249 See Plans and Pricing
Canada 2541382 FORME POSOLOGIQUE SOLIDE COMPRENANT UNE FIBRATE ET UNE STATINE (A SOLID DOSAGE FORM COMPRISING A FIBRATE AND A STATIN) See Plans and Pricing
China 1867321 A solid dosage form comprising a fibrate See Plans and Pricing
Hong Kong 1096034 A SOLID DOSAGE FORM COMPRISING A FIBRATE See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Merck
Johnson and Johnson
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.